

<!--StartFragment-->RESULT 1

SEQ ID No. 1

ADQ31356

ID ADQ31356 standard; protein; 123 AA.

XX

AC ADQ31356;

XX

DT 07-OCT-2004 (first entry)

XX

DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.

XX

KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;

KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;

KW variable region.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Region 23. .31

FT /note= "Kabat complementarity determining region (CDR)"

FT Region 31. .35

FT /note= "Chothia CDR"

FT Region 50. .66

FT /note= "Kabat/Chothia CDR"

FT Region 96. .113

FT /note= "Kabat/Chothia CDR"

XX

PN WO2004058190-A2.

XX

PD 15-JUL-2004.

XX

PF 23-DEC-2003; 2003WO-US041367.

XX

PR 23-DEC-2002; 2002US-0436147P.

XX

PA (RINA-) RINAT NEUROSCIENCE CORP.

XX

PI Shelton DL;

XX

DR WPI; 2004-525789/50.

XX

PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an individual comprises administering to the individual an amount of an anti-trkC agonist antibody.

XX

PS Disclosure; Page 24; 68pp; English.

XX

CC The present invention relates to a method for treating taxol-induced sensory neuropathy (e.g. allodynia) or cancer in an individual. The method comprises administering to the individual anti-trkC agonist antibody, which binds an epitope in domain 4 of human trk C. The present sequence is the heavy chain variable region of the anti-trkC agonist antibody.

XX

SQ Sequence 123 AA;

Query Match 100.0%; Score 658; DB 1; Length 123;
 Best Local Similarity 100.0%;
 Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
 |||||||
 Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
 Qy 61 NEKFKSRVTMTRDTSTVYMEPLLSEDATAVYCARKYYGNTRRSWYFDVWGGTTV 120

Db ||||||| 61 NEKFKSRVTMTRDTSTVYMELESSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTTV 120
Qy 121 TVS 123
Db 121 TVS 123

<!--EndFragment-->

<!--StartFragment-->RESULT 1

ADQ31357 SEQ ID No. 2

ID ADQ31357 standard; protein; 113 AA.

XX

AC ADQ31357;

XX

DT 07-OCT-2004 (first entry)

XX

DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.

XX

KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;

KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;

KW variable region.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Region 24. .38

FT /note= "Kabat/ Chothia complementarity determining region

FT (CDR)"

FT Region 54. .60

FT /note= "Kabat/ Chothia CDR"

FT Region 93. .101

FT /note= "Kabat/ Chothia CDR"

XX

PN WO2004058190-A2.

XX

PD 15-JUL-2004.

XX

PF 23-DEC-2003; 2003WO-US041367.

XX

PR 23-DEC-2002; 2002US-0436147P.

XX

PA (RINA-) RINAT NEUROSCIENCE CORP.

XX

PI Shelton DL;

XX

DR WPI; 2004-525789/50.

XX

PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an

PT individual comprises administering to the individual an amount of an anti

PT -trkC agonist antibody.

XX

PS Disclosure; Page 24; 68pp; English.

XX

CC The present invention relates to a method for treating taxol-induced

CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The

CC method comprises administering to the individual anti-trkC agonist

CC antibody, which binds an epitope in domain 4 of human trk C. The present

CC sequence is the light chain variable region of the anti-trkC agonist

CC antibody.

XX

SQ Sequence 113 AA;

Query Match 100.0%; Score 581; DB 1; Length 113;

Best Local Similarity 100.0%;

Matches 113; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DIQMTQSPSLSASVGDRVTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAA SNRGS 60

Db 1 DIQMTQSPSLSASVGDRVTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAA SNRGS 60

Qy 61 GVPSPFSGSGSGTDFFTISSLQPEDIATYYCQQSKTVPRTFGQQGT KLEIKRT 113

Db 1 |||||||

Db 61 GPVPSRFSGSGSGTDFIFTISSLQPEDIATYYCQQSKTVPRTFGQQGKLEIKRT 113

<!--EndFragment-->

<!--StartFragment-->RESULT 3
 ADQ31356
 ID ADQ31356 standard; protein; 123 AA. SEQ ID No. 4
 XX
 AC ADQ31356;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
 XX
 KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
 KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
 KW variable region.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 23. .31
 FT /note= "Kabat complementarity determining region (CDR)"
 FT Region 31. .35
 FT /note= "Chothia CDR"
 FT Region 50. .66
 FT /note= "Kabat/Chothia CDR"
 FT Region 96. .113
 FT /note= "Kabat/Chothia CDR"
 XX
 PN WO2004058190-A2.
 XX
 PD 15-JUL-2004.
 XX
 PF 23-DEC-2003; 2003WO-US041367.
 XX
 PR 23-DEC-2002; 2002US-0436147P.
 XX
 PA (RINA-) RINAT NEUROSCIENCE CORP.
 XX
 PI Shelton DL;
 XX
 DR WPI; 2004-525789/50.
 XX
 PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
 PT individual comprises administering to the individual an amount of an anti
 PT -trkC agonist antibody.
 XX
 PS Disclosure; Page 24; 68pp; English.
 XX
 CC The present invention relates to a method for treating taxol-induced
 CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
 CC method comprises administering to the individual anti-trkC agonist
 CC antibody, which binds an epitope in domain 4 of human trk C. The present
 CC sequence is the heavy chain variable region of the anti-trkC agonist
 CC antibody.
 XX
 SQ Sequence 123 AA;
 Query Match 100.0%; Score 10; DB 1; Length 123;
 Best Local Similarity 100.0%;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GYTFTSYRIH 10
 |||||||||||
 Db 26 GYTFTSYRIH 35
 <!--EndFragment-->

<!--StartFragment-->RESULT 3
 ADQ31356
 ID ADQ31356 standard; protein; 123 AA.
 XX
 AC ADQ31356;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
 XX
 KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
 KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
 KW variable region.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 23. .31
 FT /note= "Kabat complementarity determining region (CDR)"
 FT Region 31. .35
 FT /note= "Chothia CDR"
 FT Region 50. .66
 FT /note= "Kabat/Chothia CDR"
 FT Region 96. .113
 FT /note= "Kabat/Chothia CDR"
 XX
 PN WO2004058190-A2.
 XX
 PD 15-JUL-2004.
 XX
 PF 23-DEC-2003; 2003WO-US041367.
 XX
 PR 23-DEC-2002; 2002US-0436147P.
 XX
 PA (RINA-) RINAT NEUROSCIENCE CORP.
 XX
 PI Shelton DL;
 XX
 DR WPI; 2004-525789/50.
 XX
 PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
 PT individual comprises administering to the individual an amount of an anti
 PT -trkC agonist antibody.
 XX
 PS Disclosure; Page 24; 68pp; English.
 XX
 CC The present invention relates to a method for treating taxol-induced
 CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
 CC method comprises administering to the individual anti-trkC agonist
 CC antibody, which binds an epitope in domain 4 of human trk C. The present
 CC sequence is the heavy chain variable region of the anti-trkC agonist
 CC antibody.
 XX
 SQ Sequence 123 AA;

Query Match 100.0%; Score 17; DB 1; Length 123;
 Best Local Similarity 100.0%;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EIYPSNARTNYNEKFKS 17
 |||||||
 Db 50 EIYPSNARTNYNEKFKS 66

<!--EndFragment-->

<!--StartFragment-->RESULT 3
 ADQ31356
 ID ADQ31356 standard; protein; 123 AA. SEQ ID No. 6
 XX
 AC ADQ31356;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
 XX
 KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
 KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
 KW variable region.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 23. .31
 FT /note= "Kabat complementarity determining region (CDR)"
 FT Region 31. .35
 FT /note= "Chothia CDR"
 FT Region 50. .66
 FT /note= "Kabat/Chothia CDR"
 FT Region 96. .113
 FT /note= "Kabat/Chothia CDR"
 XX
 PN WO2004058190-A2.
 XX
 PD 15-JUL-2004.
 XX
 PF 23-DEC-2003; 2003WO-US041367.
 XX
 PR 23-DEC-2002; 2002US-0436147P.
 XX
 PA (RINA-) RINAT NEUROSCIENCE CORP.
 XX
 PI Shelton DL;
 XX
 DR WPI; 2004-525789/50.
 XX
 PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
 PT individual comprises administering to the individual an amount of an anti
 PT -trkC agonist antibody.
 XX
 PS Disclosure; Page 24; 68pp; English.
 XX
 CC The present invention relates to a method for treating taxol-induced
 CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
 CC method comprises administering to the individual anti-trkC agonist
 CC antibody, which binds an epitope in domain 4 of human trk C. The present
 CC sequence is the heavy chain variable region of the anti-trkC agonist
 CC antibody.
 XX
 SQ Sequence 123 AA;

Query Match 100.0%; Score 15; DB 1; Length 123;
 Best Local Similarity 100.0%;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 KYYGNTRRSWYFDV 15
 |||||||
 Db 99 KYYGNTRRSWYFDV 113

<!--EndFragment-->

<!--StartFragment-->RESULT 3
 ADQ31357
 ID ADQ31357 standard; protein; 113 AA.
 XX
 AC ADQ31357;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
 XX
 KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
 KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
 KW variable region.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 24. .38
 FT /note= "Kabat/ Chothia complementarity determining region
 (CDR)"
 FT Region 54. .60
 FT /note= "Kabat/ Chothia CDR"
 FT Region 93. .101
 FT /note= "Kabat/ Chothia CDR"
 XX
 PN WO2004058190-A2.
 XX
 PD 15-JUL-2004.
 XX
 PF 23-DEC-2003; 2003WO-US041367.
 XX
 PR 23-DEC-2002; 2002US-0436147P.
 XX
 PA (RINA-) RINAT NEUROSCIENCE CORP.
 XX
 PI Shelton DL;
 XX
 DR WPI; 2004-525789/50.
 XX
 PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
 PT individual comprises administering to the individual an amount of an anti
 PT -trkC agonist antibody.
 XX
 PS Disclosure; Page 24; 68pp; English.
 XX
 CC The present invention relates to a method for treating taxol-induced
 CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
 CC method comprises administering to the individual anti-trkC agonist
 CC antibody, which binds an epitope in domain 4 of human trk C. The present
 CC sequence is the light chain variable region of the anti-trkC agonist
 CC antibody.
 XX
 SQ Sequence 113 AA;

Query Match 100.0%; Score 15; DB 1; Length 113;
 Best Local Similarity 100.0%;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RASESIDNYGISFLA 15
 |||||||
 Db 24 RASESIDNYGISFLA 38

<!--EndFragment-->

<!--StartFragment-->RESULT 4
 ADQ31357
 ID ADQ31357 standard; protein; 113 AA.
 XX
 AC ADQ31357;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
 XX
 KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
 KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
 KW variable region.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 24. .38
 FT /note= "Kabat/ Chothia complementarity determining region
 (CDR)"
 FT Region 54. .60
 FT /note= "Kabat/ Chothia CDR"
 FT Region 93. .101
 FT /note= "Kabat/ Chothia CDR"
 XX
 PN WO2004058190-A2.
 XX
 PD 15-JUL-2004.
 XX
 PF 23-DEC-2003; 2003WO-US041367.
 XX
 PR 23-DEC-2002; 2002US-0436147P.
 XX
 PA (RINA-) RINAT NEUROSCIENCE CORP.
 XX
 PI Shelton DL;
 XX
 DR WPI; 2004-525789/50.
 XX
 PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
 PT individual comprises administering to the individual an amount of an anti
 PT -trkC agonist antibody.
 XX
 PS Disclosure; Page 24; 68pp; English.
 XX
 CC The present invention relates to a method for treating taxol-induced
 CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
 CC method comprises administering to the individual anti-trkC agonist
 CC antibody, which binds an epitope in domain 4 of human trk C. The present
 CC sequence is the light chain variable region of the anti-trkC agonist
 CC antibody.
 XX
 SQ Sequence 113 AA;

Query Match 100.0%; Score 7; DB 1; Length 113;
 Best Local Similarity 100.0%;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AASNRGS 7
 |||||||
 Db 54 AASNRGS 60
 <!--EndFragment-->

<!--StartFragment-->RESULT 3
 ADQ31357
 ID ADQ31357 standard; protein; 113 AA. SEQ ID No. 9
 XX
 AC ADQ31357;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
 XX
 KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
 KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
 KW variable region.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 24. .38
 FT /note= "Kabat/ Chothia complementarity determining region
 (CDR)"
 FT Region 54. .60
 FT /note= "Kabat/ Chothia CDR"
 FT Region 93. .101
 FT /note= "Kabat/ Chothia CDR"
 XX
 PN WO2004058190-A2.
 XX
 PD 15-JUL-2004.
 XX
 PF 23-DEC-2003; 2003WO-US041367.
 XX
 PR 23-DEC-2002; 2002US-0436147P.
 XX
 PA (RINA-) RINAT NEUROSCIENCE CORP.
 XX
 PI Shelton DL;
 XX
 DR WPI; 2004-525789/50.
 XX
 PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
 PT individual comprises administering to the individual an amount of an anti
 PT -trkC agonist antibody.
 XX
 PS Disclosure; Page 24; 68pp; English.
 XX
 CC The present invention relates to a method for treating taxol-induced
 CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
 CC method comprises administering to the individual anti-trkC agonist
 CC antibody, which binds an epitope in domain 4 of human trk C. The present
 CC sequence is the light chain variable region of the anti-trkC agonist
 CC antibody.
 XX
 SQ Sequence 113 AA;

Query Match 100.0%; Score 9; DB 1; Length 113;
 Best Local Similarity 100.0%;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QQSKTVPRT 9
 |||||||||
 Db 93 QQSKTVPRT 101

<!--EndFragment-->

<!--StartFragment-->RESULT 2
US-10-549-441-1
; Sequence 1, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-1

Query Match 100.0%; Score 658; DB 5; Length 123;
Best Local Similarity 100.0%;
Matches 123; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60

Qy 61 NEKFKSRVTMTRDTSTSTVYMELOSSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTIV 120
Db 61 NEKFKSRVTMTRDTSTSTVYMELOSSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTIV 120

Qy 121 TVS 123
Db 121 TVS 123

<!--EndFragment-->

```

<!--StartFragment-->RESULT 2
US-10-549-441-2
; Sequence 2, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-2

Query Match          100.0%;  Score 581;  DB 5;  Length 113;
Best Local Similarity 100.0%;
Matches 113;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

Qy      1 DIQMTQSPSSLSASVGDRVТИTCRASESIDNYGISFLAWYQQKPGKAPKLLIYAA
Db      1 DIQMTQSPSSLSASVGDRVТИTCRASESIDNYGISFLAWYQQKPGKAPKLLIYAA
Qy      61 GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSKTVPRTFGQGKLEIKRT 113
Db      61 GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSKTVPRTFGQGKLEIKRT 113
<!--EndFragment-->

```

<!--StartFragment-->RESULT 1
US-10-549-441-3 SEQ ID No. 4
; Sequence 3, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-3

Query Match 100.0%; Score 10; DB 5; Length 13;
Best Local Similarity 100.0%;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GYTFTSYRIH 10
Db 4 GYTFTSYRIH 13
<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-10-549-441-4 SEQ ID No. 5
; Sequence 4, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-4

Query Match 100.0%; Score 17; DB 5; Length 17;
Best Local Similarity 100.0%;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EIYPSNARTNYNEKFKS 17
Db 1 EIYPSNARTNYNEKFKS 17
<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-10-549-441-5
; Sequence 5, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-5

Query Match 100.0%; Score 15; DB 5; Length 18;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KYYYGNTRRSWYFDV 15
||| ||| ||| ||| ||| |||
Db 4 KYYYGNTRRSWYFDV 18
<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-10-549-441-6
; Sequence 6, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-6

Query Match 100.0%; Score 15; DB 5; Length 15;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RASESIDNYGISFLA 15
||| ||| ||| ||| ||| |||
Db 1 RASESIDNYGISFLA 15

<!--StartFragment-->RESULT 1
US-10-549-441-7
; Sequence 7, Application US/10549441 ; SEQ ID No. 8
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-7

Query Match 100.0%; Score 7; DB 5; Length 7;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AASNRGS 7
Db 1 AASNRGS 7
<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-10-549-441-8
; Sequence 8, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-8

Query Match 100.0%; Score 9; DB 5; Length 9;
Best Local Similarity 100.0%;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QQSKTVPRT 9
Db 1 QQSKTVPRT 9
|||
<!--EndFragment-->